

Adriano Lazzarin

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8402866/adriano-lazzarin-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

384
papers

18,538
citations

66
h-index

124
g-index

387
ext. papers

20,278
ext. citations

7.3
avg, IF

5.65
L-index

#	Paper	IF	Citations
384	Benefits of a 12-week physical activity programme on muscle and bone health in people living with HIV. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021 ,	10.3	1
383	Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105893	14.3	11
382	Molecular epidemiology of HIV-1 infection in immigrant population in northern Italy. <i>Epidemiology and Infection</i> , 2020 , 148, e19	4.3	6
381	HIV-1 recombinant forms in immigrants regularly residing in Milan, northern Italy. <i>Infection</i> , 2020 , 48, 553-558	5.8	6
380	A Mobile Application for Exercise Intervention in People Living with HIV. <i>Medicine and Science in Sports and Exercise</i> , 2020 , 52, 425-433	1.2	16
379	Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa456	1	5
378	A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study. <i>Drug Design, Development and Therapy</i> , 2019 , 13, 477-479	4.4	2
377	Diagnostic and Prognostic Value of JC Virus DNA in Plasma in Progressive Multifocal Leukoencephalopathy. <i>Clinical Infectious Diseases</i> , 2018 , 67, 65-72	11.6	7
376	Cost-effectiveness analysis of the use of daclatasvir+sofosbuvir+tribavirin (16-weeks and 12-weeks) vs sofosbuvir+tribavirin (16-weeks and 24-weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy. <i>European Journal of Health Economics</i> , 2018 , 19, 37-44	3.6	6
375	An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study. <i>Infectious Diseases</i> , 2018 , 50, 220-222	3.1	3
374	Bictegravir. <i>Current Opinion in HIV and AIDS</i> , 2018 , 13, 326-333	4.2	16
373	Darunavir for the treatment of HIV infection. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1149-1163	4	10
372	Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load. <i>PLoS ONE</i> , 2018 , 13, e0191300	3.7	3
371	Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 177-182	5.1	18
370	Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018 , 79, 617-623	3.1	6
369	Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen. <i>International Journal of Antimicrobial Agents</i> , 2018 , 52, 492-499	14.3	9
368	Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients. <i>BMC Infectious Diseases</i> , 2017 , 17, 43	4	6

367	Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfecting with HIV and HCV genotype-1: a Phase III, open-label study. <i>Hepatology International</i> , 2017 , 11, 188-198	8.8	2
366	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. <i>Lancet HIV,the</i> , 2017 , 4, e195-e204	7.8	53
365	Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1549-1550 ¹	5.1	1550 ¹
364	Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals. <i>Journal of Hepatology</i> , 2017 , 67, 415-417	13.4	6
363	NS3 protease resistance-associated substitutions in liver tissue and plasma samples from patients infected by hepatitis C virus genotype 1A or 1B. <i>Archives of Virology</i> , 2017 , 162, 2271-2277	2.6	4
362	Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients. <i>Journal of Interferon and Cytokine Research</i> , 2017 , 37, 103-111	3.5	13
361	Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial. <i>HIV Clinical Trials</i> , 2017 , 18, 135-140		25
360	Cannabinoid receptor 2-63 RR variant is independently associated with severe necroinflammation in HIV/HCV coinfecting patients. <i>PLoS ONE</i> , 2017 , 12, e0181890	3.7	7
359	Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males. <i>PLoS ONE</i> , 2017 , 12, e0186367	3.7	12
358	The use of circulating cathodic antigen rapid test and serology for diagnosis of active <i>Schistosoma mansoni</i> infection in migrants in Italy, a non-endemic country: a cross sectional study. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2017 , 112, 452-455	2.6	6
357	Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. <i>Lancet, The</i> , 2017 , 390, 2063-2072	40	169
356	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 427-434	18.8	13
355	Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. <i>Lancet HIV,the</i> , 2017 , 4, e536-e546	7.8	67
354	A pilot study of brisk walking in sedentary combination antiretroviral treatment (cART)- treated patients: benefit on soluble and cell inflammatory markers. <i>BMC Infectious Diseases</i> , 2017 , 17, 61	4	27
353	Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 632-633	5.1	7
352	Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients. <i>BMC Infectious Diseases</i> , 2017 , 17, 723	4	3
351	Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients. <i>Therapeutics and Clinical Risk Management</i> , 2017 , 13, 787-797	2.9	6
350	Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients. <i>PLoS ONE</i> , 2017 , 12, e0182007	3.7	7

349	Generic antiretrovirals for the treatment of HIV: a novel challenge for Western countries??. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2017 , 55, 381-393	2	5
348	Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI. <i>HIV Clinical Trials</i> , 2017 , 18, 118-125		11
347	Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 812-815	5.1	6
346	Marked Decrease in Lymphocyte Count in HIV/Hepatitis C Virus (HCV)-Coinfected Patients With Advanced Liver Disease During Anti-HCV Treatment With Direct-Acting Antiviral Regimens Including Ribavirin. <i>Clinical Infectious Diseases</i> , 2016 , 62, 527-8	11.6	1
345	Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir. <i>Medicine (United States)</i> , 2016 , 95, e3780	1.8	5
344	Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients. <i>Medicine (United States)</i> , 2016 , 95, e4144	1.8	5
343	Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study. <i>Clinical Infectious Diseases</i> , 2016 , 63, 821-829	11.6	35
342	Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1637-42	5.1	5
341	TM6SF2 E167K variant predicts severe liver fibrosis for human immunodeficiency/hepatitis C virus co-infected patients, and severe steatosis only for a non-3 hepatitis C virus genotype. <i>World Journal of Gastroenterology</i> , 2016 , 22, 8509-8518	5.6	9
340	HIV Clinical Pathway: A New Approach to Combine Guidelines and Sustainability of Anti-Retroviral Treatment in Italy. <i>PLoS ONE</i> , 2016 , 11, e0168399	3.7	0
339	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2015. <i>New Microbiologica</i> , 2016 , 39, 93-109	1.1	13
338	Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study). <i>New Microbiologica</i> , 2016 , 39, 290-294	1.1	4
337	Performance of commonly used genotypic assays and comparison with phenotypic assays of HIV-1 coreceptor tropism in acutely HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1391-5	5.1	9
336	Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. <i>Lancet HIV</i> , 2015 , 2, e127-36	7.8	141
335	The maraviroc expanded access program - safety and efficacy data from an open-label study. <i>HIV Clinical Trials</i> , 2015 , 16, 10-21		11
334	JC polyomavirus mutants escape antibody-mediated neutralization. <i>Science Translational Medicine</i> , 2015 , 7, 306ra151	17.5	46
333	Immortal time bias: authors' reply. <i>Aids</i> , 2015 , 29, 860-1	3.5	1
332	Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin. <i>Medicine (United States)</i> , 2015 , 94, e1876	1.8	7

331	Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy. <i>Journal of the International AIDS Society</i> , 2015 , 18, 20037	5.4	10
330	HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. <i>Retrovirology</i> , 2015 , 12, 33	3.6	36
329	Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation: authors' reply. <i>Aids</i> , 2015 , 29, 857-9	3.5	
328	Beneficial Effects of cART Initiated during Primary and Chronic HIV-1 Infection on Immunoglobulin-Expression of Memory B-Cell Subsets. <i>PLoS ONE</i> , 2015 , 10, e0140435	3.7	10
327	Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1436-9	5.1	4
326	The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. <i>Retrovirology</i> , 2014 , 11, 49	3.6	32
325	Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial. <i>Lancet Infectious Diseases</i> , 2014 , 14, 291-300	25.5	76
324	Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfecting patients. <i>Brazilian Journal of Infectious Diseases</i> , 2014 , 18, 164-9	2.8	8
323	Optimal dietary calcium intake in HIV treated patients: no femoral osteoporosis but higher cardiovascular risk. <i>Clinical Nutrition</i> , 2014 , 33, 363-6	5.9	4
322	Immunological recovery after 24 weeks of antiretroviral therapy in patients with X4 virus during primary HIV infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014 , 65, e27-9	3.1	3
321	Efficacy and safety of maraviroc vs. efavirenz in treatment-naïve patients with HIV-1: 5-year findings. <i>Aids</i> , 2014 , 28, 717-25	3.5	32
320	Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19806	5.4	4
319	Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19490	5.4	33
318	Predictors of lack of serological response to syphilis treatment in HIV-infected subjects. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19654	5.4	1
317	Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service. <i>ClinicoEconomics and Outcomes Research</i> , 2014 , 6, 409-14	1.7	6
316	Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19811	5.4	1
315	Dolutegravir: a new option for HIV treatment. <i>Future Virology</i> , 2014 , 9, 801-810	2.4	0
314	Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman. <i>International Journal of Infectious Diseases</i> , 2014 , 29, 100-2	10.5	2

313	HIV-1 Tropism Test Evaluation: Assessment and Clinical Implications. <i>ISRN Virology</i> , 2014 , 2014, 1-6		
312	Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy. <i>Aids</i> , 2014 , 28, 2407-15	3.5	15
311	Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results. <i>Aids</i> , 2014 , 28, 2269-79	3.5	19
310	Central nervous system HIV infection in "less-drug regimen" antiretroviral therapy simplification strategies. <i>Seminars in Neurology</i> , 2014 , 34, 78-88	3.2	10
309	Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤ 50 copies/ml in an observational setting. <i>Antiviral Therapy</i> , 2014 , 19, 319-24	1.6	5
308	Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting. <i>Therapeutics and Clinical Risk Management</i> , 2014 , 10, 9-15	2.9	10
307	Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study. <i>New Microbiologica</i> , 2014 , 37, 439-48	1.1	2
306	Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naïve individuals infected with hepatitis C virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 1448-50	5.1	2
305	Susac's syndrome as HIV-associated immune reconstitution inflammatory syndrome. <i>AIDS Research and Therapy</i> , 2013 , 10, 22	3	1
304	Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. <i>Journal of Infectious Diseases</i> , 2013 , 207, 740-8	7	227
303	Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. <i>Lancet Infectious Diseases</i> , 2013 , 13, 587-96	25.5	101
302	Dolutegravir in antiretroviral-naïve adults with HIV-1: 96-week results from a randomized dose-ranging study. <i>Aids</i> , 2013 , 27, 1771-8	3.5	103
301	Plasma fibroblast growth factor 23 and osteocalcin serum levels are associated with cardiovascular risk in HIV-1-infected patients receiving antiretroviral treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2960-3	5.1	4
300	Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naïve patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 1686-8	5.1	10
299	Non-invasive fibrosis biomarkers - APRI and Forns - are associated with liver stiffness in HIV-monoinfected patients receiving antiretroviral drugs. <i>Liver International</i> , 2013 , 33, 1113-20	7.9	10
298	Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients: a matched cohort study. <i>Cancer</i> , 2013 , 119, 2710-9	6.4	2
297	In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2525-32	5.1	27
296	Glucose tolerance in HIV-1 treated patients who switched from boosted-protease inhibitors to etravirine. <i>Aids</i> , 2013 , 27, 2661-3	3.5	

295	Week 96 efficacy and safety of rilpivirine in treatment-naïve, HIV-1 patients in two Phase III randomized trials. <i>Aids</i> , 2013 , 27, 939-950	3.5	108
294	Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy. <i>European Journal of Epidemiology</i> , 2012 , 27, 657-65	12.1	56
293	Efficacy and Safety of Lersivirine (UK-453,061) versus Efavirenz in Antiretroviral Treatment-Naïve HIV-1-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 1	3.1	3
292	Ten-year survival among HIV-1-infected subjects with AIDS or non-AIDS-defining malignancies. <i>International Journal of Cancer</i> , 2012 , 130, 2990-6	7.5	24
291	Mortality of HIV-infected patients with or without cancer: comparison with the general population in Italy. <i>Antiviral Therapy</i> , 2012 , 17, 447-58	1.6	9
290	Long-term remission of HIV-associated primary CNS lymphoma achieved with highly active antiretroviral therapy alone. <i>Journal of Clinical Oncology</i> , 2012 , 30, e119-21	2.2	17
289	Immune recovery and T cell subset analysis during effective treatment with maraviroc. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 2474-8	5.1	9
288	Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 213-7	5.1	26
287	Monotherapy with atazanavir as a simplification strategy: results from an observational study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012 , 60, e101-3	3.1	4
286	Safety profile of maraviroc in patients coinfecting with HIV-1 and hepatitis B or C included in the maraviroc expanded access program. <i>HIV Clinical Trials</i> , 2012 , 13, 83-9		14
285	Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK. <i>HIV Clinical Trials</i> , 2012 , 13, 228-32		29
284	Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens. <i>Aids</i> , 2012 , 26, 1837-40	3.5	11
283	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. <i>New Microbiologica</i> , 2012 , 35, 113-59	1.1	23
282	HIV protease inhibitors: present and future. <i>Future Virology</i> , 2011 , 6, 571-580	2.4	
281	Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. <i>Lancet, The</i> , 2011 , 378, 238-46	4.0	318
280	Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 56, e113-5	3.1	18
279	Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96. <i>HIV Clinical Trials</i> , 2011 , 12, 313-22		15
278	Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage. <i>Antiviral Therapy</i> , 2011 , 16, 1035-45	1.6	20

277	Disseminated <i>Rhodococcus equi</i> infection in HIV infection despite highly active antiretroviral therapy. <i>BMC Infectious Diseases</i> , 2011 , 11, 343	4	11
276	Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naïve human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. <i>Clinical Infectious Diseases</i> , 2011 , 53, 807-16	11.6	134
275	Pharmacokinetics of the raltegravir/maraviroc/etravirine combination. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1932-4	5.1	7
274	Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. <i>Journal of Infectious Diseases</i> , 2011 , 204, 103-14	7	113
273	Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. <i>Journal of Infectious Diseases</i> , 2011 , 204, 1811-5	7	87
272	Integrase and fusion inhibitors transmitted drug resistance in naïve patients with recent diagnosis of HIV-1 infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011 , 56, e51-4	3.1	12
271	Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 901-11	5.1	13
270	Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. <i>New Microbiologica</i> , 2011 , 34, 109-46	1.1	19
269	Perturbation of the natural killer cell compartment during primary human immunodeficiency virus 1 infection primarily involving the CD56 bright subset. <i>Immunology</i> , 2010 , 129, 220-33	7.8	20
268	Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. <i>Pharmacogenetics and Genomics</i> , 2010 , 20, 759-65	1.9	38
267	Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. <i>PLoS ONE</i> , 2010 , 5, e13540	3.7	73
266	Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 425-33	5.1	48
265	Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. <i>Clinical Infectious Diseases</i> , 2010 , 51, 963-72	11.6	327
264	Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. <i>Clinical Infectious Diseases</i> , 2010 , 50, 605-12	11.6	175
263	Raltegravir versus Efavirenz regimens in treatment-naïve HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 55, 39-48	3.1	187
262	Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trial. <i>Journal of Clinical Virology</i> , 2010 , 47, 253-7	14.5	4
261	An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe. <i>Pharmacogenetics and Genomics</i> , 2010 , 20, 307-14	1.9	29
260	Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. <i>Aids</i> , 2010 , 24, 924-8	3.5	38

259	Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 53, 456-63	3.1	51
258	Liver histology in HIV/hepatitis C-coinfected and HCV-monoinfected patients with persistently normal alanine aminotransferases. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010 , 54, 107-8	3.1	11
257	Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. <i>Antiviral Therapy</i> , 2010 , 15, 993-1002	1.6	29
256	Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy. <i>Antiviral Therapy</i> , 2010 , 15, 165-75	1.6	14
255	Effects of endurance exercise training on metabolic and inflammatory parameters in HIV-1-infected patients with secondary lipodystrophy and diabetes. <i>Sport Sciences for Health</i> , 2010 , 6, 23-25	1.3	1
254	Lopinavir/ritonavir + tenofovir Dual Therapy versus Lopinavir/ritonavir-Based Triple Therapy in HIV-Infected Antiretroviral Naïve Subjects: The Kalead Study. <i>Journal of Antivirals & Antiretrovirals</i> , 2010 , 02,	2	12
253	Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. <i>New Microbiologica</i> , 2010 , 33, 195-206 ^{1,1}	1.1	35
252	Survival of HIV-1 infected multidrug-resistant patients recycling enfuvirtide after a previous failure. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 51, 179-84	3.1	4
251	A step ahead on the HIV collaboratory. <i>Science</i> , 2009 , 324, 1264-5	33.3	4
250	Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. <i>Vaccine</i> , 2009 , 27, 3306-12	4.1	39
249	The preventive phase I trial with the HIV-1 Tat-based vaccine. <i>Vaccine</i> , 2009 , 28, 371-8	4.1	39
248	Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. <i>Lancet, The</i> , 2009 , 374, 796-806	4.0	539
247	Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. <i>Aids</i> , 2009 , 23, 455-60	3.5	63
246	Changes in darunavir/r resistance score after previous failure to tipranavir/r in HIV-1-infected multidrug-resistant patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 50, 192-5	3.1	7
245	Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 51, 106-8	3.1	27
244	Magnitude and determinants of CD4 recovery after HAART resumption after 1 cycle of treatment interruption. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 52, 588-94	3.1	6
243	Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. <i>Aids</i> , 2009 , 23, 2289-300	3.5	138
242	Raltegravir in treatment naïve patients. <i>European Journal of Medical Research</i> , 2009 , 14 Suppl 3, 22-9	4.8	5

241	In Vivo Treatment with Fusion Inhibitor Enfuvirtide Leads to Increased IL-12 Production by Autologous in Vitro Activated Monocytes from HIV-infected Individuals. <i>Journal of Antivirals & Antiretrovirals</i> , 2009 , 01, 043-050	2	
240	Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients. <i>Antiviral Therapy</i> , 2009 , 14, 339-347	1.6	18
239	Raltegravir with optimized background therapy for resistant HIV-1 infection. <i>New England Journal of Medicine</i> , 2008 , 359, 339-54	59.2	621
238	Recombinant human growth hormone: rationale for use in the treatment of HIV-associated lipodystrophy. <i>BioDrugs</i> , 2008 , 22, 101-12	7.9	12
237	Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. <i>New England Journal of Medicine</i> , 2008 , 359, 355-65	59.2	456
236	Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. <i>New England Journal of Medicine</i> , 2008 , 359, 1442-55	59.2	277
235	Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. <i>Aids</i> , 2008 , 22, 2187-98	3.5	30
234	The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. <i>Aids</i> , 2008 , 22, 2207-9	3.5	36
233	Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008 , 48, 324-33	3.1	42
232	NF-kappa B modulates sensitivity to apoptosis, proinflammatory and migratory potential in short-versus long-term cultured human gamma delta lymphocytes. <i>Journal of Immunology</i> , 2008 , 181, 5857-64 ^{5.3}	5.3	21
231	Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 384-7	5.1	6
230	Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARE Study. <i>AIDS Patient Care and STDs</i> , 2008 , 22, 7-16	5.8	18
229	Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008 , 47, 429-40	3.1	23
228	Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. <i>Aids</i> , 2008 , 22, 2461-9	3.5	49
227	HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy. <i>Journal of Medical Virology</i> , 2008 , 80, 201-8	19.7	13
226	Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations. <i>Journal of Medical Virology</i> , 2008 , 80, 937-41	19.7	9
225	Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy. <i>Journal of Medical Virology</i> , 2008 , 80, 766-71	19.7	35
224	Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART. <i>Journal of Medical Virology</i> , 2008 , 80, 1695-706	19.7	9

223	Access denied? The status of co-receptor inhibition to counter HIV entry. <i>Expert Opinion on Pharmacotherapy</i> , 2007 , 8, 923-33	4	36
222	Does cyclosporin A affect CCR5 and CXCR4 expression in primary HIV-1-infected patients?. <i>Cytometry Part B - Clinical Cytometry</i> , 2007 , 72, 433-41	3.4	1
221	Favorable outcome of ex-vivo purging of monocytes after the reintroduction of treatment after interruption in patients infected with multidrug resistant HIV-1. <i>Journal of Medical Virology</i> , 2007 , 79, 1640-9	19.7	5
220	Atazanavir/ritonavir: a valuable once-daily HIV protease inhibitor with little impact on lipid profile. <i>Future Virology</i> , 2007 , 2, 131-143	2.4	3
219	TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. <i>AIDS Patient Care and STDs</i> , 2007 , 21, 533-43	5.8	43
218	Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type-1 infected patients. <i>AIDS Research and Human Retroviruses</i> , 2007 , 23, 216-23	1.6	23
217	Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects. <i>European Journal of Endocrinology</i> , 2007 , 156, 503-9	6.5	33
216	Natural mucosal antibodies reactive with first extracellular loop of CCR5 inhibit HIV-1 transport across human epithelial cells. <i>Aids</i> , 2007 , 21, 13-22	3.5	30
215	Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 60, 831-6	5.1	15
214	Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. <i>Clinical Infectious Diseases</i> , 2007 , 45, 381-90	11.6	50
213	Naturally occurring C-terminally truncated STAT5 is a negative regulator of HIV-1 expression. <i>Blood</i> , 2007 , 109, 5380-9	2.2	32
212	Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. <i>Aids</i> , 2007 , 21, 1867-75	3.5	34
211	Antiretroviral treatment strategies and immune reconstitution in treatment-naïve HIV-infected patients with advanced disease. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 46 Suppl 1, S19-30	3.1	34
210	Lack of immune recovery in HIV/Leishmania co-infection treated with human recombinant IL-2. <i>Aids</i> , 2007 , 21, 1223-5	3.5	5
209	The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. <i>Aids</i> , 2007 , 21, 1273-81	3.5	232
208	Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir. <i>Aids</i> , 2007 , 21, 1648-51	3.5	16
207	Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity. <i>Aids</i> , 2007 , 21, 2366-7	3.5	0
206	Hepatitis C virus (HCV) coinfection in a cohort of HIV positive long-term non-progressors: possible protective effect of infecting HCV genotype on HIV disease progression. <i>Journal of Clinical Virology</i> , 2007 , 39, 82-6	14.5	12

205	Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. <i>Lancet, The</i> , 2007 , 369, 1169-78	40	429
204	Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. <i>Lancet, The</i> , 2007 , 369, 1261-1269	40	512
203	Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2007 , 370, 39-48	40	388
202	Immunotherapy of HIV Infection: Dendritic Cells as Targets and Tools 2007 , 515-540		
201	Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. <i>Clinical Infectious Diseases</i> , 2007 , 44, 1484-92	11.6	127
200	Significant link between sCD30 changes and HIV viremia in patients treated with HAART. <i>Journal of Medical Virology</i> , 2006 , 78, 1513-9	19.7	8
199	Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir. <i>Journal of Medical Virology</i> , 2006 , 78, 1537-41	19.7	9
198	Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4+ cell counts: a EuroSIDA study. <i>Journal of Infectious Diseases</i> , 2006 , 194, 633-41	7	63
197	Successful voriconazole therapy of disseminated <i>Fusarium verticillioides</i> infection in an immunocompromised patient receiving chemotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 57, 796-8	5.1	15
196	Comparison of an in-house and a commercial RD1-based ELISPOT-IFN-gamma assay for the diagnosis of <i>Mycobacterium tuberculosis</i> infection. <i>Clinical Medicine and Research</i> , 2006 , 4, 266-72	1.4	10
195	Ganciclovir is associated with low or undetectable Epstein-Barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma. <i>Clinical Infectious Diseases</i> , 2006 , 42, e21-5	11.6	46
194	96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. <i>Aids</i> , 2006 , 20, 711-8	3.5	166
193	Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. <i>Clinical Infectious Diseases</i> , 2006 , 43, 1347-56	11.6	80
192	Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study. <i>Clinical Infectious Diseases</i> , 2006 , 42, 1470-80	11.6	9
191	An in-house RD1-based enzyme-linked immunospot-gamma interferon assay instead of the tuberculin skin test for diagnosis of latent <i>Mycobacterium tuberculosis</i> infection. <i>Journal of Clinical Microbiology</i> , 2006 , 44, 1944-50	9.7	15
190	Oral CCR5 inhibitors: will they make it through?. <i>Expert Opinion on Investigational Drugs</i> , 2006 , 15, 451-64	5.9	6
189	Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. <i>Lancet, The</i> , 2006 , 368, 489-97	40	283
188	The effects of the Roche AMPLICOR HIV-1 MONITOR UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisons. <i>Journal of Clinical Virology</i> , 2006 , 35, 420-5	14.5	18

187	Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. <i>Blood</i> , 2006 , 107, 4825-33	2.2	60
186	Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations. <i>HIV Clinical Trials</i> , 2006 , 7, 86-96		21
185	Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). <i>Aids</i> , 2006 , 20, 795-803	3.5	117
184	Liver fibrosis in HIV-positive patients with hepatitis C virus: role of persistently normal alanine aminotransferase levels. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 41, 63-7	3.1	34
183	The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 41, 447-52	3.1	7
182	A case of HIV-associated fever of unknown origin: deficit of IL-1beta antagonistic activity and resolution with monocyte-granulocyte apheresis. <i>Aids</i> , 2006 , 20, 312-3	3.5	
181	Immunological basis for IgE hyper-production in enfuvirtide-treated HIV- positive patients. <i>Journal of Clinical Immunology</i> , 2006 , 26, 168-76	5.7	4
180	Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 40, 404-12	3.1	131
179	Thymidine kinase and deoxycytidine kinase activity in mononuclear cells from antiretroviral-naive HIV-infected patients. <i>Aids</i> , 2005 , 19, 473-9	3.5	10
178	Enfuvirtide: the first HIV fusion inhibitor. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 453-64	4	32
177	The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development. <i>Drugs</i> , 2005 , 65, 879-904	12.1	48
176	Hepatitis C virus populations in the plasma, peripheral blood mononuclear cells and cerebrospinal fluid of HIV/hepatitis C virus-co-infected patients. <i>Aids</i> , 2005 , 19 Suppl 3, S151-65	3.5	23
175	Cost-effectiveness of enfuvirtide for treatment-experienced patients with HIV in Italy. <i>HIV Clinical Trials</i> , 2005 , 6, 92-102		12
174	Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. <i>Aids</i> , 2005 , 19, 153-62	3.5	23
173	A simplified flow cytometry method of CD4 and CD8 cell counting based on thermoresistant reagents: implications for large scale monitoring of HIV-infected patients in resource-limited settings. <i>Cytometry Part B - Clinical Cytometry</i> , 2005 , 68, 43-51	3.4	17
172	Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients. <i>European Journal of Clinical Pharmacology</i> , 2005 , 61, 545-9	2.8	12
171	Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. <i>Aids</i> , 2005 , 19, 685-94	3.5	182
170	GH treatment reduces trunkal adiposity in HIV-infected patients with lipodystrophy: a randomized placebo-controlled study. <i>European Journal of Endocrinology</i> , 2005 , 153, 781-9	6.5	16

169	Determination of human papillomavirus (HPV) load and type in high-grade cervical lesions surgically resected from HIV-infected women during follow-up of HPV infection. <i>Clinical Infectious Diseases</i> , 2005 , 40, 451-7	11.6	25
168	Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen. <i>AIDS Research and Human Retroviruses</i> , 2005 , 21, 545-54	1.6	4
167	Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. <i>Clinical Infectious Diseases</i> , 2005 , 40, 738-44	11.6	121
166	Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005 , 40, 413-21	3.1	69
165	Sequencing antiretroviral drugs for long-lasting suppression of HIV replication. <i>New Microbiologica</i> , 2005 , 28, 281-97	1.1	7
164	Selected pool of peptides from ESAT-6 and CFP-10 proteins for detection of Mycobacterium tuberculosis infection. <i>Journal of Clinical Microbiology</i> , 2004 , 42, 3469-74	9.7	36
163	Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study. <i>Clinical Infectious Diseases</i> , 2004 , 38, 565-71	11.6	102
162	Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 3253-9	5.9	74
161	Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients. <i>Aids</i> , 2004 , 18, 2205-8	3.5	5
160	Comparison of IFN-alpha 2b with or without ribavirin for treatment of chronic hepatitis C in HIV-positive patients infected with hepatitis C virus genotype 3a. <i>Aids</i> , 2004 , 18, 1080-2	3.5	
159	Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance. <i>Journal of NeuroVirology</i> , 2004 , 10, 52-57	3.9	
158	Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance. <i>Journal of NeuroVirology</i> , 2004 , 10, 52-57	3.9	
157	Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease. <i>Journal of Neuroimmunology</i> , 2004 , 157, 133-9	3.5	28
156	Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance. <i>Journal of NeuroVirology</i> , 2004 , 10 Suppl 1, 52-7	3.9	18
155	The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations. <i>Annals of Neurology</i> , 2004 , 55, 687-94	9.4	35
154	Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy. <i>Journal of Medical Virology</i> , 2004 , 72, 181-6	19.7	7
153	Atazanavir—a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials. <i>Journal of the International Association of Providers of AIDS Care</i> , 2004 , 3, 92-8		43
152	Lack of reduction of thymidine kinase activity in stavudine-treated HIV-infected patients. <i>AIDS Research and Human Retroviruses</i> , 2004 , 20, 701-3	1.6	2

151	Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. <i>New England Journal of Medicine</i> , 2004 , 351, 438-50	59.2	1079
150	Screening of HIV-1 isolates by reverse heteroduplex mobility assay and identification of non-B subtypes in Italy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004 , 37, 1295-306	3.1	24
149	Nitric oxide production in HIV-1 infected patients receiving intermittent cycles of interleukin-2 and antiretrovirals. <i>HIV Clinical Trials</i> , 2004 , 5, 146-51		
148	Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome. <i>Aids</i> , 2004 , 18, 821-3	3.5	2
147	Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. <i>Aids</i> , 2004 , 18, 1137-46	3.5	58
146	Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004 , 36, 1011-9	3.1	257
145	CCR5-specific mucosal IgA in saliva and genital fluids of HIV-exposed seronegative subjects. <i>Blood</i> , 2004 , 104, 2205-6	2.2	31
144	The NIQ of Lopinavir is Predictive of a 48-Week Virological Response in Highly Treatment-Experienced HIV-1-Infected Subjects Treated with a Lopinavir/Ritonavir-Containing Regimen. <i>Antiviral Therapy</i> , 2004 , 9, 537-543	1.6	10
143	Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003 , 34, 58-61	3.1	100
142	Long-term effect of highly active antiretroviral therapy on cervical lesions in HIV-positive women. <i>Aids</i> , 2003 , 17, 2136-8	3.5	17
141	Escape of monocyte-derived dendritic cells of HIV-1 infected individuals from natural killer cell-mediated lysis. <i>Aids</i> , 2003 , 17, 2291-8	3.5	46
140	Virological rebound after suppression on highly active antiretroviral therapy. <i>Aids</i> , 2003 , 17, 1741-51	3.5	83
139	Improved thymopoietic potential in aviremic HIV infected individuals treated with HAART by intermittent IL-2 administration. <i>Aids</i> , 2003 , 17, 1621-30	3.5	1
138	Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients. <i>Aids</i> , 2003 , 17, 2669-71	3.5	11
137	Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003 , 32, 268-80	3.1	51
136	Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. <i>Aids</i> , 2003 , 17, 1993-5	3.5	40
135	Pretreatment of chronic active hepatitis C in patients coinfecting with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003 , 33, 146-52	3.1	35
134	Expression of CD4 on human peripheral blood neutrophils. <i>Blood</i> , 2003 , 101, 4452-6	2.2	47

133	Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2003 , 284, E274-80	6	61
132	The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. <i>Journal of NeuroVirology</i> , 2003 , 9 Suppl 1, 73-80	3.9	100
131	Double-edged effect of Vgamma9/Vdelta2 T lymphocytes on viral expression in an in vitro model of HIV-1/mycobacteria co-infection. <i>European Journal of Immunology</i> , 2003 , 33, 252-63	6.1	14
130	CD30 ligation differentially affects CXCR4-dependent HIV-1 replication and soluble CD30 secretion in non-Hodgkin cell lines and in gamma delta T lymphocytes. <i>European Journal of Immunology</i> , 2003 , 33, 3136-45	6.1	12
129	In vivo modulation of leukocyte trafficking receptor following therapeutic purging of myeloid cells: implications for treatment of HIV infection and other immune disorders. <i>Clinical Immunology</i> , 2003 , 109, 355-355	9	
128	In vivo modulation of leukocyte trafficking receptor following therapeutic purging of myeloid cells: implications for treatment of HIV infection and other immune disorders. <i>Clinical Immunology</i> , 2003 , 109, 355-8	9	21
127	Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. <i>Journal of Clinical Microbiology</i> , 2003 , 41, 5080-4	9.7	102
126	Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. <i>New England Journal of Medicine</i> , 2003 , 348, 2186-95	59.2	582
125	Rapid diagnosis of mycobacterial infections and quantitation of Mycobacterium tuberculosis load by two real-time calibrated PCR assays. <i>Journal of Clinical Microbiology</i> , 2003 , 41, 4565-72	9.7	73
124	Detection of Pneumocystis carinii and characterization of mutations associated with sulfa resistance in bronchoalveolar lavage samples from human immunodeficiency virus-infected subjects. <i>Journal of Clinical Microbiology</i> , 2003 , 41, 2709-12	9.7	17
123	Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure. <i>AIDS Research and Human Retroviruses</i> , 2003 , 19, 1151-3	1.6	15
122	Epstein-Barr virus DNA load in cerebrospinal fluid and plasma of patients with AIDS-related lymphoma. <i>Journal of NeuroVirology</i> , 2002 , 8, 432-8	3.9	57
121	Tumor necrosis factor alpha, interleukin 2, and soluble interleukin 2 receptor levels in human immunodeficiency virus type 1-infected individuals receiving intermittent cycles of interleukin 2. <i>AIDS Research and Human Retroviruses</i> , 2002 , 18, 491-9	1.6	7
120	Molecular studies of cerebrospinal fluid in human immunodeficiency virus type 1-associated opportunistic central nervous system diseases--an update. <i>Journal of NeuroVirology</i> , 2002 , 8 Suppl 2, 122-8	3.9	5
119	Detection of DNA of lymphotropic herpesviruses in plasma of human immunodeficiency virus-infected patients: frequency and clinical significance. <i>Vaccine Journal</i> , 2002 , 9, 1222-8		8
118	Selective granulocyte/monocyte apheresis in the treatment of HIV-infected patients: short-term and long-term effects on immunological and virological parameters. <i>Perfusion (United Kingdom)</i> , 2002 , 17 Suppl, 47-51	1.9	18
117	A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. <i>Journal of Infectious Diseases</i> , 2002 , 185, 1251-60	7	121
116	Direct detection of Helicobacter pylori mutations associated with macrolide resistance in gastric biopsy material taken from human immunodeficiency virus-infected subjects. <i>Journal of Clinical Microbiology</i> , 2002 , 40, 2234-7	9.7	11

115	Non-cytotoxic inhibition of HIV-1 infection by unstimulated CD8+ T lymphocytes from HIV-exposed-uninfected individuals. <i>Aids</i> , 2002 , 16, 1003-8	3.5	18
114	Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infection. <i>Blood</i> , 2002 , 100, 1381-7	2.2	95
113	Neurobrucellosis with spinal cord abscess of the dorsal tract: a case report. <i>International Journal of Infectious Diseases</i> , 2002 , 6, 149-50	10.5	11
112	Retrospective analysis of HHV-8 viremia and cellular viral load in HIV-seropositive patients receiving interleukin 2 in combination with antiretroviral therapy. <i>Blood</i> , 2002 , 100, 1575-1578	2.2	11
111	Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. <i>Journal of Clinical Investigation</i> , 2002 , 109, 681-688	15.9	94
110	Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. <i>Journal of Clinical Investigation</i> , 2002 , 109, 681-8	15.9	42
109	The role of stage-specific oligonucleotide primers in providing effective laboratory support for the molecular diagnosis of reactivated <i>Toxoplasma gondii</i> encephalitis in patients with AIDS. <i>Journal of Medical Microbiology</i> , 2002 , 51, 879-890	3.2	37
108	No Protective Effect of Acyclovir on HIV Disease Progression in a Cohort of Hsv-2/HIV-Infected Individuals. <i>Antiviral Therapy</i> , 2002 , 7, 289-291	1.6	7
107	Evolution of the E2 region of hepatitis C virus in an infant infected by mother-to-infant transmission. <i>Journal of Medical Virology</i> , 2001 , 64, 476-81	19.7	9
106	Immunovirological improvement in partially HAART responder HIV-infected patients by monocyte adsorption apheresis. <i>Journal of Clinical Apheresis</i> , 2001 , 16, 35-6	3.2	3
105	The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. <i>Journal of NeuroVirology</i> , 2001 , 7, 358-63	3.9	99
104	Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid. <i>AIDS Research and Human Retroviruses</i> , 2001 , 17, 377-83	1.6	37
103	The binding subunit of pertussis toxin inhibits HIV replication in human macrophages and virus expression in chronically infected promonocytic U1 cells. <i>Journal of Immunology</i> , 2001 , 166, 1863-70	5.3	30
102	Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine. <i>Aids</i> , 2001 , 15, 2423-9	3.5	27
101	Comparison of three nucleic acid amplification assays of cerebrospinal fluid for diagnosis of cytomegalovirus encephalitis. <i>Journal of Clinical Microbiology</i> , 2001 , 39, 1148-51	9.7	20
100	Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. <i>Journal of Infectious Diseases</i> , 2001 , 184, 547-51	7	151
99	Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy. <i>Journal of Infectious Diseases</i> , 2001 , 183, 1476-84	7	43
98	Expression and activation of a C-terminal truncated isoform of STAT5 (STAT5 Delta) following interleukin 2 administration or AZT monotherapy in HIV-infected individuals. <i>Clinical Immunology</i> , 2001 , 99, 75-81	9	10

97	Soluble CD23 in cerebrospinal fluid: a marker of AIDS-related non-Hodgkin's lymphoma in the brain. <i>Aids</i> , 2001 , 15, 1109-13	3.5	12
96	Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. <i>Aids</i> , 2001 , 15, 2385-95	3.5	49
95	The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. <i>Aids</i> , 2001 , 15, 201-9	3.5	41
94	Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count. <i>Aids</i> , 2000 , 14, 2257-63	3.5	33
93	Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy. <i>Aids</i> , 2000 , 14, 1887-97	3.5	56
92	The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2000 , 45, 495-501	3.5	27
91	Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor β -chain repertoire and reduces the level of T-cell oligoclonality. <i>Blood</i> , 2000 , 95, 1743-1751	2.2	36
90	CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro. <i>Journal of Immunology</i> , 2000 , 164, 3426-33	5.3	101
89	Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. <i>Clinical Infectious Diseases</i> , 2000 , 30, 95-9	11.6	111
88	Anti-cell antibodies in exposed seronegative individuals with HIV type 1-neutralizing activity. <i>AIDS Research and Human Retroviruses</i> , 2000 , 16, 109-15	1.6	37
87	CCR2-64I polymorphism, syncytium-inducing human immunodeficiency virus strains, and disease progression. <i>Journal of Infectious Diseases</i> , 2000 , 182, 1579-80	7	9
86	Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection. <i>Journal of Infectious Diseases</i> , 2000 , 182, 950-4	7	34
85	Plasma Viral Load Concentrations in Women and Men From Different Exposure Categories and With Known Duration of HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000 , 25, 56-62	3.1	28
84	Shorter survival of SDF1-3'M/3'M homozygotes linked to CD4+ T cell decrease in advanced human immunodeficiency virus type 1 infection. <i>Journal of Infectious Diseases</i> , 2000 , 182, 311-5	7	59
83	Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 3155-7	5.9	11
82	Ex vivo modulation of RANTES and sCD30 by proinflammatory stimuli in HIV-seropositive and -negative individuals. <i>Clinical Immunology</i> , 2000 , 97, 102-8	9	3
81	Management Strategies for Herpesvirus Infections of the CNS. <i>CNS Drugs</i> , 2000 , 14, 95-113	6.7	1
80	Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. <i>AIDS Research and Human Retroviruses</i> , 2000 , 16, 2019-35	1.6	143

79	Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. <i>Journal of Clinical Investigation</i> , 2000 , 105, 777-82	15.9	27
78	Effects of hydroxyurea on T cell count changes during primary HIV infection. <i>Aids</i> , 2000 , 14, 619-22	3.5	7
77	Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment. <i>Aids</i> , 2000 , 14, 1656-8	3.5	28
76	Splenic irradiation versus splenectomy for severe, refractory HIV-related thrombocytopenia: effects on platelet counts and immunological status. <i>Aids</i> , 2000 , 14, 1664-7	3.5	5
75	Metabolic disorders in a cohort of patients treated with highly aggressive antiretroviral therapies during primary HIV-1 infection. <i>Aids</i> , 2000 , 14, 1861-2	3.5	6
74	Detection of rifampin resistance in <i>Mycobacterium tuberculosis</i> by double gradient-denaturing gradient gel electrophoresis. <i>Antimicrobial Agents and Chemotherapy</i> , 1999 , 43, 2550-4	5.9	23
73	Constitutive Activation of STATs Upon In Vivo Human Immunodeficiency Virus Infection. <i>Blood</i> , 1999 , 94, 4202-4209	2.2	72
72	Anti-CD4 antibodies in exposed seronegative adults and in newborns of HIV type 1-seropositive mothers: a follow-up study. <i>AIDS Research and Human Retroviruses</i> , 1999 , 15, 1079-85	1.6	17
71	Infection of circulating CD34+ cells by HHV-8 in patients with Kaposi's sarcoma. <i>Journal of Investigative Dermatology</i> , 1999 , 113, 613-6	4.3	33
70	Remission of AIDS-associated progressive multifocal leukoencephalopathy after zidovudine therapy. <i>Journal of Neurology</i> , 1999 , 246, 723-5	5.5	33
69	Dual role of TNF-alpha in NK/LAK cell-mediated lysis of chronically HIV-infected U1 cells. Concomitant enhancement of HIV expression and sensitization of cell-mediated lysis. <i>European Journal of Immunology</i> , 1999 , 29, 3654-62	6.1	14
68	Spatial working memory in asymptomatic HIV-infected subjects. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 1999 , 11, 387-91	2.7	12
67	Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection. <i>Aids</i> , 1999 , 13, 791-6	3.5	39
66	A Comparison of Exposure Groups in the EuroSIDA Study: Starting Highly Active Antiretroviral Therapy (HAART), Response to HAART, and Survival. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999 , 22, 369	3.1	43
65	A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999 , 22, 369-78	3.1	108
64	CCR2 polymorphism and HIV disease. Swiss HIV Cohort. <i>Nature Medicine</i> , 1998 , 4, 252-3	50.5	56
63	Evaluation of the detection of human papillomavirus genotypes in cervical specimens by hybrid capture as screening for precancerous lesions in HIV-positive women. <i>Journal of Medical Virology</i> , 1998 , 56, 133-7	19.7	21
62	Herpes simplex virus infections of the central nervous system in human immunodeficiency virus-infected patients: clinical management by polymerase chain reaction assay of cerebrospinal fluid. <i>Clinical Infectious Diseases</i> , 1998 , 27, 303-9	11.6	58

61	Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. <i>Aids</i> , 1998 , 12, 1327-32	3.5	201
60	Changes in use of antiretroviral therapy in regions of Europe over time. EuroSIDA Study Group. <i>Aids</i> , 1998 , 12, 2031-9	3.5	42
59	Cytomegalovirus pneumonia in AIDS patients: value of cytomegalovirus culture from BAL fluid and correlation with lung disease. <i>Chest</i> , 1998 , 113, 919-23	5.3	27
58	Cerebrospinal fluid HIV-1 RNA levels: correlation with HIV encephalitis. <i>Aids</i> , 1998 , 12, 389-94	3.5	90
57	Interleukin-6 Induces Monocyte Chemotactic Protein-1 in Peripheral Blood Mononuclear Cells and in the U937 Cell Line. <i>Blood</i> , 1998 , 91, 258-265	2.2	186
56	A Randomized Controlled Study for the Evaluation of the Activity of a Triple Combination of Zidovudine, Thymosin- α and Interferon- γ in HIV-Infected Individuals with CD4 Counts between 200 and 500 cells/mm ³ . <i>Antiviral Therapy</i> , 1998 , 3, 103-111	1.6	4
55	Acute pancreatitis during primary HIV-1 infection. <i>New England Journal of Medicine</i> , 1997 , 336, 1836-7	59.2	23
54	Varicella-zoster virus (VZV) DNA in cerebrospinal fluid of patients infected with human immunodeficiency virus: VZV disease of the central nervous system or subclinical reactivation of VZV infection?. <i>Clinical Infectious Diseases</i> , 1997 , 25, 634-9	11.6	61
53	Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele. <i>Journal of Experimental Medicine</i> , 1997 , 186, 455-60	16.6	107
52	Human immunodeficiency virus type 1 glycoprotein 120-specific T lymphocytes provide intermolecular help for anti-CD4 autoantibody production in exposed uninfected subjects. <i>AIDS Research and Human Retroviruses</i> , 1997 , 13, 1461-9	1.6	12
51	Low doses of zidovudine plus didanosine are less effective than higher doses of didanosine monotherapy: a randomized trial in patients pretreated with zidovudine. <i>Clinical Microbiology and Infection</i> , 1997 , 3, 629-633	9.5	
50	Genetic polymorphism of CCR5 gene and HIV disease: the heterozygous (CCR5/delta ccr5) genotype is neither essential nor sufficient for protection against disease progression. Swiss HIV Cohort. <i>European Journal of Immunology</i> , 1997 , 27, 3223-7	6.1	35
49	How many HIV-infected individuals may be defined as long-term nonprogressors? A report from the Italian Seroconversion Study. Italian Seroconversion Study Group (ISS). <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997 , 14, 243-8		25
48	Serum polymerase chain reaction for cytomegalovirus DNA for monitoring ganciclovir treatment in AIDS patients. <i>Scandinavian Journal of Infectious Diseases</i> , 1996 , 28, 347-51		3
47	Isolation of spindle-shaped cell populations from primary cultures of Kaposi's sarcoma of different stage. <i>Cancer Letters</i> , 1996 , 100, 125-32	9.9	20
46	Factors associated with the CD4+ lymphocyte count at diagnosis of acquired immunodeficiency syndrome. The AIDS IN EUROPE Study Group. <i>Journal of Clinical Epidemiology</i> , 1996 , 49, 1253-8	5.7	10
45	Plasma levels of soluble CD30, tumour necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcome. <i>Aids</i> , 1996 , 10, F45-50	3.5	60
44	Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients. <i>Aids</i> , 1996 , 10, 951-8	3.5	140

43	HIV-1-specific immunity in persistently seronegative individuals at high risk for HIV infection. <i>Immunology Letters</i> , 1996 , 51, 39-43	4.1	26
42	Temporal lobe electroencephalogram power modifications during olfactory stimulation in HIV-infected patients. <i>AIDS Research and Human Retroviruses</i> , 1996 , 12, 547-51	1.6	5
41	Cytokines and soluble receptor changes in the transition from primary to early chronic HIV type 1 infection. <i>AIDS Research and Human Retroviruses</i> , 1996 , 12, 325-31	1.6	30
40	Better efficacy of twice-monthly than monthly aerosolised pentamidine for secondary prophylaxis of <i>Pneumocystis carinii</i> pneumonia in patients with AIDS. An Italian multicentric randomised controlled trial. The Italian PCP Study Group. <i>Journal of Infection</i> , 1995 , 31, 99-105	18.9	6
39	Modeling incidence rate ratio and rate difference: additivity or multiplicativity of human immunodeficiency virus parenteral and sexual transmission among intravenous drug users. Northern Italy Seronegative Drug Addicts Study. <i>American Journal of Epidemiology</i> , 1995 , 141, 16-24	3.8	5
38	A controlled trial of zidovudine in primary human immunodeficiency virus infection. <i>New England Journal of Medicine</i> , 1995 , 333, 408-13	59.2	274
37	In vitro production of type 1 and type 2 cytokines by peripheral blood mononuclear cells from high-risk HIV-negative intravenous drug users. <i>Aids</i> , 1995 , 9, 691-4	3.5	26
36	Clinical characteristics and prognostic value of acute retroviral syndrome among injecting drug users. Italian Seroconversion Study. <i>Aids</i> , 1995 , 9, 597-604	3.5	36
35	The efficiency of male-to-female and female-to-male sexual transmission of the human immunodeficiency virus: a study of 730 stable couples. Italian Study Group on HIV Heterosexual Transmission. <i>Epidemiology</i> , 1994 , 5, 570-5	3.1	189
34	Transitory expansion of a CD3+TcR gamma/delta+CD16+ lymphocytic population in two patients with advanced human immunodeficiency virus infection and high levels of natural killer activity. <i>AIDS Research and Human Retroviruses</i> , 1994 , 10, 711-5	1.6	3
33	Hepatitis C virus infection in blood donors with indeterminate results in second-generation recombinant immunoblot assay. <i>Transfusion</i> , 1994 , 34, 555-6	2.9	2
32	Beta-endorphin content in HIV-infected HuT78 cell line and in peripheral lymphocytes from HIV-positive subjects. <i>Peptides</i> , 1994 , 15, 769-75	3.8	14
31	Diagnosis of virus-associated opportunistic diseases of the central nervous system in patients with HIV infection by polymerase chain reaction on cerebrospinal fluid. <i>Annals of the New York Academy of Sciences</i> , 1994 , 724, 170-2	6.5	3
30	Pharmacokinetics of zidovudine in HIV-positive patients with liver disease. <i>Journal of Clinical Pharmacology</i> , 1994 , 34, 782-6	2.9	9
29	Polymerase chain reaction for <i>Toxoplasma gondii</i> DNA in the cerebrospinal fluid of AIDS patients with focal brain lesions. <i>Aids</i> , 1994 , 8, 1691-4	3.5	38
28	TH1 and TH2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. <i>Aids</i> , 1994 , 8, 757-62	3.5	134
27	Long-term treatment with zidovudine in patients with human immunodeficiency virus (HIV)-associated thrombocytopenia: modes of response and correlation with markers of HIV replication. <i>European Journal of Haematology</i> , 1993 , 50, 17-21	3.8	11
26	Comparison of two dose regimens of zidovudine in an open, randomized, multicentre study for severe HIV-related thrombocytopenia. <i>Aids</i> , 1993 , 7, 209-12	3.5	24

25	Discrete regions of HIV-1 gp41 defined by syncytia-inhibiting affinity-purified human antibodies. <i>Aids</i> , 1993 , 7, 167-74	3.5	25
24	Mother-to-child transmission of hepatitis C virus detected by nested polymerase chain reaction. <i>Journal of Infectious Diseases</i> , 1992 , 165, 720-3	7	136
23	Monocyte-derived macrophage function in HIV-infected subjects: in vitro modulation by rIFN-gamma and rGM-CSF. <i>Clinical Immunology and Immunopathology</i> , 1992 , 62, 176-82		28
22	Parenteral and sexual transmission of human immunodeficiency virus in intravenous drug users: a study of seroconversion. The Northern Italian Seronegative Drug Addicts (NISDA) Study. <i>American Journal of Epidemiology</i> , 1992 , 135, 225-33	3.8	86
21	Rheumatoid factors and circulating immune complexes in HIV-infected individuals. <i>Aids</i> , 1991 , 5, 1441-6	3.5	15
20	Positive modification of injecting behavior among intravenous heroin users from Milan and northern Italy 1987-1989. NISDA Study. <i>Addiction</i> , 1991 , 86, 91-102	4.6	33
19	Acute ataxia coincident with seroconversion for anti-HIV. <i>Journal of Neurology</i> , 1991 , 238, 356-7	5.5	13
18	Man-to-Woman Sexual Transmission of the Human Immunodeficiency Virus. <i>Archives of Internal Medicine</i> , 1991 , 151, 2411		47
17	A controlled study of inhaled pentamidine for primary prevention of <i>Pneumocystis carinii</i> pneumonia. <i>New England Journal of Medicine</i> , 1991 , 324, 1079-83	59.2	150
16	Zidovudine and frequency of HIV-induced diffuse leukoencephalopathy. <i>Lancet, The</i> , 1991 , 337, 1488	4.0	7
15	Kappa light chain predominance in serum and cerebrospinal fluid from human immunodeficiency virus type 1 (HIV-1)-infected patients. <i>Journal of Neuroimmunology</i> , 1991 , 32, 259-68	3.5	7
14	Maternal predictors of HIV vertical transmission. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 1991 , 42, 131-6	2.4	5
13	HIV-related severe thrombocytopenia in intravenous drug users. <i>Aids</i> , 1990 , 4, 29-34	3.5	24
12	Risk behaviour and HTLV-1 seropositivity in injecting drug users. <i>Addiction</i> , 1990 , 85, 686-7	4.6	2
11	Diagnostic and prognostic significance of beta 2-microglobulin during HIV infection. <i>Research in Clinic and Laboratory</i> , 1990 , 20, 105-11		1
10	Clinical and immunological aspects of HIV infection in drug addicts. <i>Clinical Immunology and Immunopathology</i> , 1989 , 50, S166-76		17
9	The natural history of HIV infection in intravenous drug users: risk of disease progression in a cohort of seroconverters. <i>Aids</i> , 1989 , 3, 87-90	3.5	41
8	Thymostimulin treatment in AIDS-related complex. <i>Clinical Immunology and Immunopathology</i> , 1988 , 47, 253-61		7

7	Human immunodeficiency virus gp120 and p24 oligoclonal antibody in acquired immunodeficiency syndrome cerebrospinal fluid and sera. <i>Annals of the New York Academy of Sciences</i> , 1988 , 540, 611-4	6.5	4
6	Recovery of HIV-related retroviruses from Italian patients with AIDS or AIDS-related complex and from asymptomatic at-risk individuals. <i>Annals of the New York Academy of Sciences</i> , 1987 , 511, 390-400	6.5	24
5	Human immunodeficiency virus (HIV) seropositivity in intravenous (i.v.) drug abusers in three cities of Italy: possible natural history of HIV infection in i.v. drug addicts in Italy. <i>Journal of Medical Virology</i> , 1987 , 23, 241-8	19.7	11
4	Risk of human immunodeficiency virus infection in multiple transfused patients. <i>Transfusion</i> , 1987 , 27, 217	2.9	
3	Pulmonary candidiasis in a heroin addict: some remarks on its aetiology and pathogenesis. <i>Addiction</i> , 1985 , 80, 103-4	4.6	5
2	Structural skull defects in type IV Ehlers-Danlos syndrome. <i>British Journal of Dermatology</i> , 1984 , 110, 122-4	4	4
1	Lymph node finding in drug abusers. <i>American Journal of Clinical Pathology</i> , 1984 , 82, 749-50	1.9	5